A Clear Upgrade Signal
BTIG has raised its recommendation on Nuvation Bio (NYSE:NUVB) to buy, emphasizing the company’s recent acquisition of AnHeart Therapeutics as the primary catalyst.
Strategic Acquisition Benefits
The investment firm highlighted the acquisition as a key development that will equip Nuvation with a potentially groundbreaking drug candidate, taletrectinib, intended for the treatment of ROS1+ non-small cell lung cancer (NSCLC).
Comparative Advantage
The analysts at BTIG pointed out that taletrectinib demonstrates a more promising drug profile compared to Bristol Myers’ (BMY) repotrectinib, popularly known as Augtyro, already in circulation as a treatment for the same disease.
Anticipated Market Entry
Reflecting on regulatory requirements, BTIG expressed confidence in Nuvation’s ability to introduce taletrectinib to the US market as early as late 2025. The analysts speculated peak sales for the drug could reach an impressive $1.4 billion.
Setting the Bar High
BTIG unveiled a bold target price of $5 for the stock, backing their positive outlook on Nuvation’s growth potential post-AnHeart acquisition.
